How Longitudinal Biological Age Tracking Could Change Healthy Aging
Most biological age tests answer a single question: How old are you biologically? But an equally important question is often left unanswered: Has anything actually changed over time?
Many biological age assessments provide only a one-time measurement. While useful as a baseline, they may not show whether lifestyle changes, therapies, or other interventions are making a measurable difference.
As interest in longevity and preventive healthcare grows, longitudinal biological age tracking is emerging as a more comprehensive approach. By comparing results over time, researchers and clinicians can better understand changes in brain and overall biological health.
A Multimodal Approach to Measuring Biological Aging
NeuroAge Therapeutics has developed a platform that combines multiple health measurements into a single NeuroAge Score. Rather than relying on one biomarker, the platform integrates:
- Cognitive assessments
- Brain MRI
- Genetic analysis
- DEXA body composition imaging
- Blood biomarkers
This multimodal approach is designed to provide a broader view of biological and brain aging through baseline and follow-up assessments.
Founded by Dr. Christin Glorioso, MD, PhD (MIT/Harvard), NeuroAge collaborates with clinical and diagnostic partners to support longitudinal measurement using validated biomarker panels.
Recent Milestones
NeuroAge continues to expand its platform through several recent initiatives, including:
- Younger 2027, a six-month biological aging study featuring baseline and follow-up clinical assessments.
- Strategic collaborations with TruDiagnostic, Harvard FaceAge, and Vero Bioscience to integrate epigenetic, facial, and functional aging metrics.
- An Ultra Panel offering access to proteomic and methylation aging clocks, full-body DEXA imaging, and brain MRI.
- A scientific advisory network with researchers affiliated with MIT, Harvard, Yale, and Stanford.
- A $50,000 sponsor-supported prize pool recognizing measurable improvements in biological age.
- The Younger 2027 Conference, taking place on January 11–12, 2027, at Fort Mason in San Francisco, featuring experts including Dr. Steve Horvath and Dr. Ray Mak.
Why It Matters
With nearly 55 million people worldwide living with dementia, there is growing interest in tools that can monitor brain and biological health over time. Longitudinal assessments combined with multiple biomarkers may provide deeper insights than a single biological age measurement alone.
NeuroAge Therapeutics is among the companies advancing this area of longevity research through a comprehensive, data-driven approach to measuring biological aging.
Learn more about innovative companies like NeuroAge Therapeutics on Propelx.com. Accredited investors can register to explore investment opportunities across 200+ diversified deep tech companies.
